Trail Ridge Investment Advisors LLC Invests $1.30 Million in United Therapeutics Corporation $UTHR

Trail Ridge Investment Advisors LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,400 shares of the biotechnology company’s stock, valued at approximately $1,300,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new position in United Therapeutics during the 2nd quarter worth $2,868,735,000. Wellington Management Group LLP grew its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Norges Bank acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $293,418,000. Avoro Capital Advisors LLC increased its stake in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $168,188,006.77. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 434,075 shares of company stock valued at $233,942,595. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.0%

Shares of NASDAQ UTHR opened at $512.88 on Tuesday. The firm has a market capitalization of $22.00 billion, a P/E ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59. The firm’s 50-day moving average price is $532.35 and its 200-day moving average price is $538.04. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $6.41 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.